ARK Genomic Revolution ETF (ARKG) Analysis: Genomics Innovation Amid Sector Rotation
Key Takeaways
- ARK Genomic Revolution ETF (ARKG) is an actively managed thematic ETF targeting companies advancing the genomics revolution across healthcare and related sectors.
- The fund typically holds 33–60 equity positions, with a concentrated portfolio emphasizing gene editing, synthetic biology, and AI-driven diagnostics.
- Primary exposure centers on the healthcare sector, particularly biotechnology and life sciences innovation.
- Expense ratio stands at 0.75%, reflecting its active management approach and specialized thematic focus.
- Key risks include high volatility tied to regulatory developments in gene editing and capital flows into early-stage biotech firms.
- Structural growth drivers encompass advances in CRISPR technology, personalized medicine, and integration of artificial intelligence in genomics.
ARK Genomic Revolution ETF (ARKG) Overview
ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund (ETF) launched on October 31, 2014, by ARK Investment Management LLC. The fund seeks long-term growth of capital by investing primarily in equity securities of companies involved in the genomics revolution. It does not track a traditional index but follows an active strategy centered on technological and scientific advancements in genomics that extend and enhance the quality of human and other life.
The ETF typically maintains 40–60 holdings, though recent portfolios have featured approximately 33–35 positions. Top holdings as of recent data include Twist Bioscience Corporation (TWST), CRISPR Therapeutics AG (CRSP), Tempus AI Inc. (TEM), 10x Genomics Inc. (TXG), and Personalis Inc. (PSNL). These companies focus on areas such as synthetic DNA, gene editing, AI-powered oncology, and single-cell analysis. Sector allocation is overwhelmingly concentrated in healthcare, with nearly all assets in biotechnology and life sciences firms.
ARKG carries an expense ratio of 0.75%. As an actively managed thematic ETF, it employs ongoing research-driven rebalancing rather than fixed index rules, allowing flexibility to adapt to evolving genomics opportunities.
Industry and Thematic Landscape
The genomics space encompasses companies developing tools and therapies that leverage DNA sequencing, gene editing, and related technologies to transform medicine. Structural growth drivers include rapid progress in CRISPR-Cas9 and base editing platforms, expanding applications in oncology and rare diseases, and the convergence of artificial intelligence with genomic data analysis.
Capital flows into the sector benefit from increasing venture funding and strategic partnerships between biotech firms and large pharmaceutical companies. Regulatory developments, such as approvals for gene therapies by agencies like the U.S. Food and Drug Administration, serve as key catalysts. Macroeconomic factors including interest rate environments influence risk appetite for high-growth, early-stage companies in this field.
Potential headwinds encompass clinical trial setbacks, pricing pressures on novel therapies, and evolving intellectual property landscapes around gene-editing technologies. Broader healthcare policy shifts and competition from traditional pharmaceutical approaches also shape the environment.
Performance and Positioning Snapshot
In recent market cycles, ARKG has exhibited sensitivity to sector rotation within healthcare and innovation themes. Performance has reflected broader sentiment toward genomics and biotechnology, with movements tied to earnings reports from key holdings and shifts in investor focus between growth-oriented and value-oriented segments.
During periods of heightened interest in personalized medicine and AI applications in drug discovery, the fund has captured upside from its concentrated positions. Conversely, in environments favoring defensive healthcare or amid regulatory uncertainty, positioning has led to more pronounced volatility compared with broader market benchmarks. The active strategy allows adjustments based on fundamental developments in top holdings rather than passive rebalancing.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover actionable insights tailored to thematic and sector-specific opportunities.
2026 Outlook and Key Factors to Monitor
Looking ahead to 2026, the genomics sector is positioned to benefit from continued maturation of gene-editing platforms and broader adoption of AI in therapeutic development. Structural drivers include expanding clinical pipelines for CRISPR-based treatments and growing integration of multi-omics data in precision medicine initiatives. Capital flows may accelerate as more therapies reach commercialization stages, though expense considerations for actively managed thematic ETFs like ARKG warrant ongoing evaluation relative to lower-cost passive alternatives in the biotech space.
Macro risks include potential shifts in monetary policy affecting growth stock valuations and geopolitical factors influencing supply chains for specialized reagents and equipment. Policy developments around healthcare reimbursement and intellectual property protections could shape competitive dynamics. Earnings cycles of top holdings, particularly those advancing late-stage trials, will remain central to fund positioning. Investors should also monitor the evolving landscape of competing thematic ETFs and any changes in ARK’s active management approach to maintain alignment with the genomics thesis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ARKG turns positive, indicating new upward trend
ARKG saw its Momentum Indicator move above the 0 level on June 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on June 16, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for ARKG moved above the 200-day moving average on May 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 205 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARKG broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health